----
Current ValuationThe current P/E ratio is -1.80, above the reasonable range, cheaper than 9.96% of the time in the past 1 years, and the industry ranks 130/256, the industry Median -1.11.
-1.8xP/E
$3.27Stock price
$-1.82Earnings per share
-1.8xP/E
Stock price$3.27Earnings per share$-1.82
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.92x
- Typical range
- -4.07x–-2.02x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -61.21x | 154.30% | $63.94B |
BAYZFUSBayer Aktiengesellschaft | -24.08x | -- | $48.51B |
BAYRYUSBayer | -23.99x | -- | $48.34B |
VTRSUSViatris | -50.34x | 107.68% | $20.67B |
ELANUSElanco Animal Health | -56.54x | 129.36% | $11.25B |
VREOFUSVIREO GROWTH INC | -115.63x | -- | $7.76B |
AXSMUSAxsome Therap | -39.64x | 21.12% | $7.60B |
CURLFUSCuraleaf Holdings, Inc. | -115.94x | -- | $6.03B |
BLTEUSBelite Bio | -57.96x | 29.87% | $5.93B |
MANEUSVeraDermics | -55.60x | 97.44% | $5.80B |
DFTXUSDefinium Therapeutics | -13.55x | 54.55% | $4.79B |
EWTXUSEdgewise Therapeutics | -21.65x | 207.38% | $4.27B |
RGCUSRegencell Bioscience | -324.76x | -- | $3.80B |
AMLXUSAmylyx Pharmaceuticals | -22.45x | 1.76% | $3.41B |
ELVNUSEnliven Therapeutics | -28.72x | 5.59% | $3.04B |
TARSUSTarsus Pharmaceuticals | -64.39x | 256.39% | $2.99B |
BHCUSBausch Health | -2.19x | 569.84% | $2.41B |
SUPNUSSupernus Pharma | -21.53x | 66.18% | $2.37B |
MBXUSMBX Biosciences | -22.40x | 31.12% | $2.34B |
PRGOUSPerrigo | -1.28x | 100.10% | $2.21B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
